α1-Adrenergic Receptor Antibodies in Patients With Primary Hypertension

HP Luther, V Homuth, G Wallukat - Hypertension, 1997 - Am Heart Assoc
HP Luther, V Homuth, G Wallukat
Hypertension, 1997Am Heart Assoc
Autoimmune mechanisms have been proposed to play a role in the pathogenesis of primary
(essential) hypertension. Autoantibodies against the α1-adrenergic receptor have been
described in patients with malignant and secondary hypertension. To investigate the
incidence of autoantibodies against the α1-adrenoceptor in patients with primary
hypertension, we examined the immunoglobulin fractions of sera from 54 patients with
primary hypertension and 26 normotensive control subjects for the presence of …
Autoimmune mechanisms have been proposed to play a role in the pathogenesis of primary (essential) hypertension. Autoantibodies against the α1-adrenergic receptor have been described in patients with malignant and secondary hypertension. To investigate the incidence of autoantibodies against the α1-adrenoceptor in patients with primary hypertension, we examined the immunoglobulin fractions of sera from 54 patients with primary hypertension and 26 normotensive control subjects for the presence of autoantibodies against the α1-adrenoceptor. Sera from 24 patients (44%) and 3 subjects (12%) were positive. An epitope analysis of 16 autoantibody-positive immunoglobulin fractions revealed that in two thirds of the cases, the antibodies were directed against the first extracellular loop of the α1-adrenoceptor and in one third, against the second. The autoantibodies had a positive chronotropic effect on isolated neonatal rat cardiomyocytes, an effect that was blocked by α1-adrenergic antagonists. Since the functional characteristics of the autoantibodies showed no desensitization phenomena, they may play a role in elevating peripheral vascular resistance and promoting cardiac hypertrophy in patients with primary hypertension.
Am Heart Assoc